Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WDVAX
- Development stage
- Phase 1
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
WDVAX is an investigational, patient-specific cancer vaccine designed for the treatment of metastatic melanoma. It consists of a dendritic cell-activating scaffold that incorporates autologous tumor lysate (derived from the patient's own melanoma cells), granulocyte-macrophage colony-stimulating factor (GM-CSF), and a CpG oligonucleotide (a Toll-like receptor 9 agonist) onto a microporous poly-lactide-co-glycolide (PLGA) matrix polymer scaffold. This biomaterial-based vaccine acts as a physical antigen-presenting structure, recruiting and activating dendritic cells and other immune-stimulating cells in vivo to induce anti-tumor immune responses. The approach aims to amplify CD8+ T cell responses while blocking regulatory cells, thereby enhancing immunotherapy efficacy in patients with metastatic melanoma[1][2][3][4].
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on WDVAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WDVAX.